Human Normal Immunoglobulin (Iv)

• Pulse corticosteroids or/and Immunoglobulins to treat fulminant Myocarditis: a double-blind randomized controlled adaptive trial (The CORIUM… Pending
  2023-506599-28-01 Phase II 1 country Assistance Publique Hopitaux De Paris
• A double-blind, randomised, placebo-controlled, first-in-human (FIH) Phase I/IIa, multi-centre trial to assess safety, tolerability, and imm… Pending
  2024-515627-10-00 Phase I (FiH) 3 countries Toleranzia AB
• PREV-CART - “A multicentric phase III randomized clinical trial open-label, comparing immunoglobulin replacement therapy (IgRT) and antibiot… Pending
  2025-521571-30-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• A study to assess efficacy and safety of empasiprubart versus IVIg in adults with CIDP ("emvigorate") Recruiting
  2024-520097-36-00 Phase III 19 countries Argenx
• A Phase III, Open-label, Single Arm, Prospective, Multicenter Study to Assess Efficacy and Safety of Kedrion Intravenous Human Normal Immuno… Recruiting
  2023-507115-35-00 Phase III 5 countries Kedrion S.p.A.
• Multicenter, Open-Label, Randomized Study of Nipocalimab or IVIG in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (F… Recruiting
  2023-509434-19-00 Phase III 4 countries Janssen Cilag International
• Safety, Tolerability, and Efficacy of NVG-2089 in Participants with Immune Thrombocytopenia Recruiting
  2024-520359-26-00 Phase II 3 countries Nuvig Therapeutics Inc.
• An open-label study to assess safety, efficacy, and cellular kinetics of YTB323 in treatment-resistant generalized myasthenia gravis Recruiting
  2024-513589-20-00 Phase I/II 1 country Novartis Pharma AG
• Early immunotherapy with intravenous immunoglobulin, cyclophosphamide and methylprednisolone in patients with anti-Hu-associated paraneoplas… Recruiting
  2023-506942-22-01 Phase II 1 country Assistance Publique Hopitaux De Paris
• A Phase-2b, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-NMDA Receptor Enc… Recruiting
  2023-504686-23-00 Phase II 2 countries Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
• A study to assess the efficacy and safety of Empasiprubart versus IVIg in adults with Multifocal Motor Neuropathy Ended
  2024-516473-72-00 Phase III 19 countries Argenx
• LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis Ended
  2024-512676-36-00 Phase II/III 12 countries St. Anna Childrens Cancer Research Institute GmbH
• Intravenous Immunoglobulin plus oral prednisone or high-dose dexamethasone, for adults with immune thrombocytopenia (ITP) with moderate and … Ended
  2024-516403-16-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• IPAD Trial Ended
  2024-513124-41-00 Phase III 1 country Universitair Medisch Centrum Utrecht
• STRENSIQ® Immunogenicity Study Ended
  2022-502793-17-00 Phase IV 1 country Alexion Pharmaceuticals Inc.

Showing 1–15 of 15 trials